DGAP-News: Ergomed PLC

DIESE PRESSEMITTEILUNG UND DIE DARIN ENTHALTENEN INFORMATIONEN DIENEN NICHT DER DIREKTEN ODER INDIREKTEN VERÖFFENTLICHUNG ODER VERBREITUNG, IM GANZEN ODER IN AUSZÜGEN, IN DEN ODER IN DIE VEREINIGTEN STAATEN VON AMERIKA, AUSTRALIEN, KANADA, JAPAN, REPUBLIK VON IRLAND ODER REPUBLIK VON SÜDAFRIKA ODER EINE ANDERE JURISDIKTION, IN DER EIN SOLCHES VORGEHEN UNGESETZMÄSSIG WÄRE

Ergomed plc gibt Platzierungsergebnis bekannt

London, UK - 28. September 2017: Ergomed plc ("Ergomed" oder "das Unternehmen"; AIM: ERGO LN, Xetra: 2EM GR), ein auf pharmazeutische Dienstleistungen und Arzneimittelentwicklung spezialisiertes Unternehmen, freut sich das Ergebnis einer heute angekündigten Platzierung (die "Platzierung") bekannt zu geben.

Insgesamt wurden 1.757.576 neue Stammaktien des Unternehmens im Nennwert von je 1 Pence pro Aktie (die "Platzierungsaktien") zu einem Preis von 165 Pence pro Aktie (der "Platzierungspreis") platziert, wodurch ein Bruttoemissionserlös von GBP 2,9 Mio. (vor Aufwendungen) erzielt wird, der die Akquisition der PSR Group BV in Teilen finanziert.

Die auszugebenden Platzierungsaktien entsprechen etwa 4,3% des bestehenden Grundkapitals des Unternehmens. Der Platzierungspreis entspricht einem Abschlag von etwa 4,1% auf den volumengewichteten Durchschnittskurs der Aktien des Unternehmens während der letzten 30 Handelstage.

Die Platzierung wurde von Numis Securities Limited ("Numis") und N+1 Singer Advisory LLP ("N+1 Singer") als Joint Bookrunners durchgeführt. Soweit nicht anders definiert gilt für die in dieser Mitteilung verwendeten hervorgehobenen Begriffe die Bedeutung, welche ihnen in der der Mitteilung, die das Unternehmen heute Morgen um 7.00 Uhr BST veröffentlicht hat, zugewiesen wurde.

Beteiligungen von Organmitgliedern (Directors)

Die Beteiligung von Organmitgliedern von Ergomed, die Platzierungsaktien zum Platzierungspreis aufgenommen haben, gestaltet sich wie folgt:

Zulassung
Für die Platzierungsaktien ist der Antrag auf Zulassung zum Handel an der Londoner Börse (AIM) ("Zulassung") bereits gestellt worden. Derzeit wird erwartet, dass die Abwicklung und die Zulassung aller Platzierungsaktien am oder um den 2. Oktober 2017 herum um 8.00 Uhr BST stattfinden wird. Die Platzierung hängt unter anderem von dem Wirksamwerden der Zulassung ab und davon, ob die Platzierungsvereinbarung unwiderruflich wird und nicht gemäß ihrer Konditionen für nichtig erklärt wird.

Gesamtstimmrechte
Nach der Zulassung wird sich die neue Gesamtzahl der Stammaktien im Nennwert von je 1 Pence pro Aktie am Grundkapital der Gesellschaft und die Zahl der Stimmrechte auf 42.680.813 belaufen. Der obige Wert kann von den Aktionären als Richtwert in der Berechnung genutzt werden, mithilfe der sie bestimmen können, inwiefern sie unter Berücksichtigung der Offenlegungs- und Transparenzbestimmungen der Finanzaufsichtsbehörden dazu verpflichtet sind, ihre Beteiligung oder die Veränderung ihrer Beteiligung an dem Unternehmen mitzuteilen.

Nachstehend die veröffentlichte Pressemitteilung in voller Länge.

Anmerkung: Bitte beachten Sie, dass die einzig offizielle Pressemitteilung die vom Unternehmen in englischer Sprache veröffentlichte Meldung ist. Die obige Zusammenfassung und Übersetzung dient lediglich der vereinfachten Informationsbereitstellung.

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN, IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF IRELAND OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO.

Ergomed plc

Result of Placing

London, UK - 28 September 2017: Ergomed plc (AIM: ERGO) ("Ergomed" or the "Company"), a specialised pharmaceutical services and drug development company, is pleased to announce the result of the placing announced earlier today (the "Placing").

A total of 1,757,576 new ordinary shares in the Company of 1p each (the "Placing Shares") have been conditionally placed at a price of 165p per Placing Share (the "Placing Price"), raising proceeds of £2.9m (before expenses) to part-fund the acquisition of PSR Group BV.

The Placing Shares to be issued represent approximately 4.3% of the Company's existing issued ordinary share capital. The Placing Price represents a discount of approximately 4.1% to the Company's last 30 trading days volume weighted average price.

Numis Securities Limited ("Numis") and N+1 Singer Advisory LLP ("N+1 Singer") have acted as joint bookrunners in respect of the Placing. Other than where defined, capitalised terms used in this announcement have the meanings given to them in the announcement released by the Company this morning at 7.00 a.m.

Director participation

The participation of Directors of Ergomed who have taken up Placing Shares at the Placing Price is as follows:

Admission
Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM ("Admission"). It is currently expected that settlement of all of the Placing Shares and Admission will take place at 8.00 a.m. on or around 2 October 2017. The Placing is conditional upon, inter alia, Admission becoming effective and the Placing Agreement becoming unconditional and not being terminated in accordance with its terms.

Total voting rights
Following Admission the number of ordinary shares of 1 penny each in the capital of the Company in issue and number of voting rights will be 42,680,813. The above figure may be used by Shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

Enquiries:

About Ergomed

Ergomed provides specialist services to the pharmaceutical industry and develops drugs both wholly-owned and through partnerships. Ergomed's fast-growing, profitable service offering spans all phases of clinical development and post-approval pharmacovigilance and medical information. Drawing on more than 20 years of expertise in drug development, Ergomed is also building a growing portfolio of drug development partnerships and programmes, including wholly-owned proprietary products for the treatment of surgical bleeding. For further information, visit: http://ergomedplc.com

About PSR

PSR, established in 1998, is a full service specialist orphan drug CRO and recognised as a leading expert in the rare disease niche. PSR specialises in running complex orphan drug development programs requiring innovative regulatory and clinical approaches as well as pricing and reimbursement strategies. Besides outsourced project solutions, PSR provides insourced staffing solutions (orphan drug teams), temporary & permanent staffing, interim management solutions as well as training / coaching career programs.

PSR's dedication to the rare disease landscape is exemplified by an extensive track record of orphan drug projects in a wide range of therapeutic areas, its continued efforts to achieve true patient centricity and its societal commitments by participation in fundraising activities and public-private partnerships. For further information, visit: http://www.psr-group.com.
This announcement contains inside information which is disclosed in accordance with the Market Abuse Regulation.

Each of Numis Securities Limited and Nplus1 Singer Advisory LLP, both of which are regulated in the UK by the Financial Conduct Authority, is acting for the Company and no one else in connection with the Placing, and will not be responsible to any person other than the Company for providing the regulatory and legal protections afforded to their respective clients nor for providing advice in relation to the contents of this Announcement or any matter, transaction or arrangement referred to in it.

This Announcement includes statements, estimates, opinions and projections with respect to anticipated future performance of the Company or future events ("forward-looking statements") which reflect various assumptions concerning anticipated results or events which may or may not prove to be correct. These forward looking statements can be identified by the use of forward looking terminology, including the terms "anticipates", "target", "believes", "estimates", "expects", "intends", "may", "plans", "projects", "should" or "will", or, in each case, their negative or other variations or comparable terminology or by discussions of strategy, plans, objectives, goals, future events or intentions. Such forward-looking statements reflect current expectations based on the current business plan and various other assumptions and involve significant risks and uncertainties and should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not such results will be achieved. As a result, prospective investors should not rely on such forward-looking statements due to the inherent uncertainty therein. No representation or warranty is given as to the completeness or accuracy of the forward-looking statements contained in this Announcement. Forward-looking statements speak only as of the date of such statements and, except as required by the FCA, the London Stock Exchange or applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. No statement in this Announcement is intended to be a profit forecast and no statement in this Announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company. The price of shares and the income from them may go down as well as up and investors may not get back the full amount invested on disposal of the Placing Shares.

The distribution of this Announcement and the offering of the Placing Shares in certain jurisdictions may be restricted by law. No action has been taken by the Company or the Bookrunners that would permit an offering of the Placing Shares or possession or distribution of this Announcement or any other offering or publicity material relating to the Placing Shares in any jurisdiction where action for that purpose is required. Persons into whose possession this Announcement comes are required by the Company and the Bookrunners to inform themselves about, and to observe, such restrictions.

The Placing Shares to be issued pursuant to the Placing will not be admitted to trading on any stock exchange other than the London Stock Exchange.

Neither the content of the Company's website nor any website accessible by hyperlinks on the Company's website is incorporated in, or forms part of, this Announcement.